Gene Therapy Medicinal Products: Non-clinical Safety Studies
Currently, gene therapy medicinal products (GTMPs) are actively developed in many countries, including the Russian Federation. However, the use of GTMPs raises class-specific safety concerns.The aim of the study was to determine the main requirements for non-clinical safety testing of GTMPs, to iden...
Saved in:
Main Authors: | O. V. Astapova, A. A. Berchatova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2023-03-01
|
Series: | Безопасность и риск фармакотерапии |
Subjects: | |
Online Access: | https://www.risksafety.ru/jour/article/view/329 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Experience of using gene replacement therapy with Zolgensma® (onasemnogene abeparvovec) in real clinical practice in Russia
by: S. B. Artemyeva, et al.
Published: (2022-02-01) -
Safety issues of gene therapy
by: S. E. Ipatov, et al.
Published: (2022-11-01) -
Gene therapy of neurodegenerative diseases: achievements, developments, and clinical implementation challenges
by: E. V. Melnikova, et al.
Published: (2023-06-01) -
Challenges in development and authorisation of gene therapy products
by: A. A. Soldatov, et al.
Published: (2022-04-01) -
Viral and non-viral vectors in gene therapy: current state and clinical perspectives
by: Guannan Geng, et al.
Published: (2025-08-01)